374 related articles for article (PubMed ID: 20795758)
1. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor.
Sutlu T; Stellan B; Gilljam M; Quezada HC; Nahi H; Gahrton G; Alici E
Cytotherapy; 2010 Dec; 12(8):1044-55. PubMed ID: 20795758
[TBL] [Abstract][Full Text] [Related]
2. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
3. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
Tam YK; Martinson JA; Doligosa K; Klingemann HG
Cytotherapy; 2003; 5(3):259-72. PubMed ID: 12850795
[TBL] [Abstract][Full Text] [Related]
5. Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy.
Meehan KR; Wu J; Webber SM; Barber A; Szczepiorkowski ZM; Sentman C
Cytotherapy; 2008; 10(1):30-7. PubMed ID: 18202972
[TBL] [Abstract][Full Text] [Related]
6. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy.
Granzin M; Soltenborn S; Müller S; Kollet J; Berg M; Cerwenka A; Childs RW; Huppert V
Cytotherapy; 2015 May; 17(5):621-32. PubMed ID: 25881519
[TBL] [Abstract][Full Text] [Related]
7. Selection and expansion of natural killer cells for NK cell-based immunotherapy.
Becker PS; Suck G; Nowakowska P; Ullrich E; Seifried E; Bader P; Tonn T; Seidl C
Cancer Immunol Immunother; 2016 Apr; 65(4):477-84. PubMed ID: 26810567
[TBL] [Abstract][Full Text] [Related]
8. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process.
Spanholtz J; Preijers F; Tordoir M; Trilsbeek C; Paardekooper J; de Witte T; Schaap N; Dolstra H
PLoS One; 2011; 6(6):e20740. PubMed ID: 21698239
[TBL] [Abstract][Full Text] [Related]
9. PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.
Guo Y; Feng X; Jiang Y; Shi X; Xing X; Liu X; Li N; Fadeel B; Zheng C
Oncotarget; 2016 Jul; 7(30):48360-48374. PubMed ID: 27356741
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies.
Masuyama J; Murakami T; Iwamoto S; Fujita S
Cytotherapy; 2016 Jan; 18(1):80-90. PubMed ID: 26549384
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of serum-free media formulations in feeder cell-stimulated expansion of natural killer cells.
Moseman JE; Foltz JA; Sorathia K; Heipertz EL; Lee DA
Cytotherapy; 2020 Jun; 22(6):322-328. PubMed ID: 32278551
[TBL] [Abstract][Full Text] [Related]
12. How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment?
Fernández L; Leivas A; Valentín J; Escudero A; Corral D; de Paz R; Vela M; Bueno D; Rodríguez R; Torres JM; Díaz-Almirón M; López-Collazo E; Martinez-Lopez J; Pérez-Martínez A
Transfusion; 2018 Jun; 58(6):1340-1347. PubMed ID: 29542132
[TBL] [Abstract][Full Text] [Related]
13. Production of human natural killer cells for adoptive immunotherapy using a computer-controlled stirred-tank bioreactor.
Pierson BA; Europa AF; Hu WS; Miller JS
J Hematother; 1996 Oct; 5(5):475-83. PubMed ID: 8938519
[TBL] [Abstract][Full Text] [Related]
14. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy.
Spanholtz J; Tordoir M; Eissens D; Preijers F; van der Meer A; Joosten I; Schaap N; de Witte TM; Dolstra H
PLoS One; 2010 Feb; 5(2):e9221. PubMed ID: 20169160
[TBL] [Abstract][Full Text] [Related]
15. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
Berg M; Lundqvist A; McCoy P; Samsel L; Fan Y; Tawab A; Childs R
Cytotherapy; 2009; 11(3):341-55. PubMed ID: 19308771
[TBL] [Abstract][Full Text] [Related]
16. Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21.
Thangaraj JL; Phan MT; Kweon S; Kim J; Lee JM; Hwang I; Park J; Doh J; Lee SH; Vo MC; Chu TH; Song GY; Ahn SY; Jung SH; Kim HJ; Cho D; Lee JJ
Cancer Immunol Immunother; 2022 Mar; 71(3):613-625. PubMed ID: 34282497
[TBL] [Abstract][Full Text] [Related]
17. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.
Shah N; Martin-Antonio B; Yang H; Ku S; Lee DA; Cooper LJ; Decker WK; Li S; Robinson SN; Sekine T; Parmar S; Gribben J; Wang M; Rezvani K; Yvon E; Najjar A; Burks J; Kaur I; Champlin RE; Bollard CM; Shpall EJ
PLoS One; 2013; 8(10):e76781. PubMed ID: 24204673
[TBL] [Abstract][Full Text] [Related]
18. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.
Lapteva N; Durett AG; Sun J; Rollins LA; Huye LL; Fang J; Dandekar V; Mei Z; Jackson K; Vera J; Ando J; Ngo MC; Coustan-Smith E; Campana D; Szmania S; Garg T; Moreno-Bost A; Vanrhee F; Gee AP; Rooney CM
Cytotherapy; 2012 Oct; 14(9):1131-43. PubMed ID: 22900959
[TBL] [Abstract][Full Text] [Related]
19. Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients.
Peragine N; Torelli GF; Mariglia P; Pauselli S; Vitale A; Guarini A; Foà R
Cancer Immunol Immunother; 2015 Feb; 64(2):201-11. PubMed ID: 25341808
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer.
Razmara AM; Farley LE; Harris RM; Judge SJ; Lammers M; Iranpur KR; Johnson EG; Dunai C; Murphy WJ; Brown CT; Rebhun RB; Kent MS; Canter RJ
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
